Nitric Oxide Particles Help Infected Moths Survive
The research-stage approach offers a possible non-antibiotic route as bacteria grow harder to kill with standard drugs.
Updated on Nov. 3, 2026 in Life Sciences
Live Poll
Should scientists rely less on animal testing when developing new medicines?
Researchers at the University of Reading developed nitric oxide-releasing particles that helped infected wax moth larvae survive bacterial infections, with nine in ten treated larvae surviving compared with around six in ten untreated. The work is research-stage, published in the Journal of Drug Delivery Science and Technology, and has not been tested in people.
Why it matters
Bacteria are becoming harder to kill with antibiotics, pushing researchers toward alternative treatments that work differently. The study also fits a broader effort to develop insect and invertebrate tests that could reduce reliance on mammal experiments.
The evidence comes from wax moth larvae, each weighing about a quarter of a gram, infected with skin-infection bacteria and checked over three days. Survival rose from around six in ten untreated to nine in ten after treatment, and flask tests showed a 10,000 to 100,000-fold drop in bacteria after one day. Whether the effect holds in mammals or people has not been established.
The players
University of Reading
A UK university whose School of Pharmacy led the study on nitric oxide-releasing particles for treating bacterial infections.
Al-Farabi Kazakh National University
A university in Kazakhstan that partnered with the University of Reading on the research team.
The details
Nitric oxide is a small gas the body uses in signaling, and here it was packed into particles far smaller than a speck of dust. Those particles release the gas slowly over several hours rather than all at once. In the experiment, larvae were infected with bacteria and then injected with the particles one hour later, allowing the slow-release gas to act against the infection over time.
Timeline
Study published Tuesday, November 3, 2026, in the Journal of Drug Delivery Science and Technology.
Larvae were checked for three days after infection.
The Tech Race
The particles sit within a wider push to find antibacterial approaches that do not depend on antibiotics, which are losing effectiveness against resistant bacteria. The same team is also developing insect and invertebrate tests as a way to reduce reliance on mammal experiments, a trajectory the study fits into.
Nothing here is available to patients, and the particles are not yet a treatment for people. Any future use would depend on further studies beyond these insect and flask experiments.
The takeaway
Watch for follow-up studies in mammals, since that is the step needed before any clinical path opens. The particle-based approach is a candidate worth tracking as antibiotic resistance keeps narrowing treatment options.
Further reading
For more on how scientists are tackling infections that resist standard drugs, explore our Life Sciences coverage.
Source note: This article includes information reported by News-Medical.
Live Poll
Should scientists rely less on animal testing when developing new medicines?
